<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03325075</url>
  </required_header>
  <id_info>
    <org_study_id>VAL-181388-P101</org_study_id>
    <secondary_id>W911NF-13-1-0417</secondary_id>
    <nct_id>NCT03325075</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Immunogenicity of VAL-181388 in Healthy Subjects</brief_title>
  <official_title>A Phase 1, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Immunogenicity of VAL-181388 in Healthy Adults in a Non Endemic Chikungunya Region</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ModernaTX, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Defense Advanced Research Projects Agency</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>ModernaTX, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical study will assess the safety, tolerability, and immunogenicity of VAL-181388 in&#xD;
      healthy subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 15, 2017</start_date>
  <completion_date type="Actual">November 1, 2019</completion_date>
  <primary_completion_date type="Actual">November 1, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double Blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Types of adverse events (AEs), serious adverse events (SAEs), adverse events of special interest (AESI) and laboratory abnormalities</measure>
    <time_frame>Through 13 months of study participation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of adverse events (AEs), serious adverse events (SAEs), adverse events of special interest (AESI) and laboratory abnormalities</measure>
    <time_frame>Through 13 months of study participation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of adverse events (AEs), serious adverse events (SAEs), adverse events of special interest (AESI) and laboratory abnormalities</measure>
    <time_frame>Through 13 months of study participation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of seroconversion to CHIKV measured by neutralization assay in comparison with baseline</measure>
    <time_frame>Through 13 months of study participation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Chikungunya Virus</condition>
  <arm_group>
    <arm_group_label>VAL-181388</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VAL-181388</intervention_name>
    <description>Escalating dose levels</description>
    <arm_group_label>VAL-181388</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Saline</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 to 49 years of age&#xD;
&#xD;
          -  Body mass index between 18 and 35 kg/m2&#xD;
&#xD;
          -  In good health as determined by medical history&#xD;
&#xD;
          -  Female subjects must be non pregnant and non lactating and meet one of the following&#xD;
             criteria: a) post menopausal b) surgically sterile, or c) of childbearing potential&#xD;
             and agree to use an adequate contraception method&#xD;
&#xD;
          -  Male subjects must use an acceptable method of birth control through 3 months after&#xD;
             the final vaccination&#xD;
&#xD;
          -  Agrees to comply with the study procedures and provides written informed consent&#xD;
&#xD;
          -  Has access to a consistent and reliable means of telephone contact and agrees to stay&#xD;
             in contact with the study site for the duration of the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any ongoing, symptomatic acute or chronic illness requiring medical or surgical care&#xD;
&#xD;
          -  Female of childbearing potential and has a positive pregnancy test at screening or on&#xD;
             the day of vaccination&#xD;
&#xD;
          -  Abnormal vital signs or screening safety laboratory test results including liver&#xD;
             enzyme tests&#xD;
&#xD;
          -  Administration of an investigational product within 60 days, or 5 half-lives,&#xD;
             whichever is longer&#xD;
&#xD;
          -  Administration of any live attenuated vaccines within 4 weeks before enrollment or&#xD;
             inactive vaccines within 2 weeks before enrollment, or plans to receive any vaccine&#xD;
             during the active vaccination period&#xD;
&#xD;
          -  Prior administration of a vaccine for CHIKV, dengue, Yellow Fever, tick-borne&#xD;
             encephalitis, a history of confirmed or suspected CHIKV infection, or has lived in a&#xD;
             CHIKV-endemic area greater than 1 year or cumulative stay of greater than 30 days in 5&#xD;
             years&#xD;
&#xD;
          -  Prior administration of investigational agent using formulations similar to VAL-181388&#xD;
&#xD;
          -  A history of hypersensitivity or serious reactions to previous vaccinations&#xD;
&#xD;
          -  Any known or suspected autoimmune disease or immunosuppressive condition, acquired or&#xD;
             congenital, as determined by medical history and/or physical examination&#xD;
&#xD;
          -  A history of inflammatory arthritis&#xD;
&#xD;
          -  Any neurologic disorder&#xD;
&#xD;
          -  Prior administration of immunoglobulins and/or any blood products within the 3 months&#xD;
             preceding the administration of the study drug or plans to receive such products at&#xD;
             any time during the study&#xD;
&#xD;
          -  Any chronic administration of an immunosuppressant or other immune modifying drug&#xD;
&#xD;
          -  Daily or every other day administration of antipyretic or analgesic medication&#xD;
&#xD;
          -  Any acute illness at the time of enrollment&#xD;
&#xD;
          -  Any significant disorder of coagulation requiring ongoing or intermittent treatment&#xD;
&#xD;
          -  A history of idiopathic urticaria&#xD;
&#xD;
          -  A history of alcohol abuse or drug addiction&#xD;
&#xD;
          -  A positive test result for drugs of abuse&#xD;
&#xD;
          -  The subject has any abnormality or permanent body art (eg, tattoo) that, in the&#xD;
             opinion of the investigator, would obstruct the ability to observe local reactions at&#xD;
             the injection site&#xD;
&#xD;
          -  Any condition that, in the opinion of the investigator, would pose a health risk to&#xD;
             the subject if enrolled or could interfere with evaluation of the study drug or&#xD;
             interpretation of study results&#xD;
&#xD;
          -  A positive test result for hepatitis B surface antigen, hepatitis C virus antibody, or&#xD;
             human immunodeficiency virus types 1 or 2 antibodies&#xD;
&#xD;
          -  A history of active cancer (malignancy) in the last 10 years&#xD;
&#xD;
          -  Donation of blood or blood products &gt; 450 mL within 30 days of dosing&#xD;
&#xD;
          -  Is an employee or first degree relative of the Sponsor, CRO, or study site personnel&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Optimal Research</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>October 20, 2017</study_first_submitted>
  <study_first_submitted_qc>October 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2017</study_first_posted>
  <last_update_submitted>January 16, 2020</last_update_submitted>
  <last_update_submitted_qc>January 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>VAL-181388</keyword>
  <keyword>Chikungunya vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chikungunya Fever</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

